The objective of this CPG is for it to be used as a tool to improve the clinical management of men with prostate cancer, which in Spain is usually decided in specialised care, in addition to providing relevant information on this subject for other health professionals attending to people with this disease, the patients and their families.

The guide summarises the evidence available for the key issues in prostate cancer clinical management, and is aimed at provide healthcare professionals and patients with the means to share decision making. It is not mandatory nor does it replace the clinical judgment of health personnel.

The target population for the guide is adult males with a histological check or clinical diagnosis in accordance with a primary prostate adenocarcinoma. In other words, it is not designed for asymptomatic men with elevated levels of prostate-specific antigen (PSA) without a histopathological diagnosis of prostate cancer, nor for patients with metastasis in the prostate from other tumours, nor for children and adults with other malignant tumours in the prostate, both epithelial and non-epithelial, such as the cell carcinoma and rhabdomyosarcoma.

The health area involved is specialist care.

The recommendations are presented depending on their clinical situation:

1. Localised prostate cancer: definition, risk factors, clinical management and monitoring following treatment with intent to cure.
   
2. Locally advanced prostate cancer: definition and clinical management.
   
3. Prostate cancer in PSA relapse after treatment with intent to cure: definition and clinical management.
   
4. Disseminated prostate cancer: definition and clinical management.

The guide aims to advise on different clinical management alternatives, such as surgery (open or laparoscopic prostatectomy), external radiation therapy (including 3D-CRT, IMRT) and/or brachytherapy; expectant management (watchful waiting or active surveillance), hormonal manipulation, which includes androgen ablation (orchiectomy, oestrogen, LHRH agonists), antiandrogens (steroidal and non-steroidal) and combined hormone therapies; and other treatments, such as chemotherapy (cytotoxic agents), bisphosphonates, radiopharmaceuticals, cryotherapy and high intensity ultrasound (HIFU).

We have not provided information on how to go about early detection (screening), diagnosis or staging of these patients.